Intra-Cellular Therapies Inc ITCI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/29/24 EDT
72.30quote price arrow down-0.96 (-1.31%)
Volume
509,795
52 week range
45.50 - 84.89
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close72.30
  • 52 Week High84.89
  • 52 Week High Date04/16/24
  • 52 Week Low45.50
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap7.538B
  • Shares Out104.26M
  • 10 Day Average Volume2.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.01
  • YTD % Change0.95

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close72.30
  • 52 Week High84.89
  • 52 Week High Date04/16/24
  • 52 Week Low45.50
  • 52 Week Low Date10/30/23
  • Market Cap7.538B
  • Shares Out104.26M
  • 10 Day Average Volume2.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.01
  • YTD % Change0.95

RATIOS/PROFITABILITY

  • EPS (TTM)-1.46
  • P/E (TTM)-49.59
  • Fwd P/E (NTM)-108.07
  • EBITDA (TTM)-158.853M
  • ROE (TTM)-22.39%
  • Revenue (TTM)464.37M
  • Gross Margin (TTM)92.73%
  • Net Margin (TTM)-30.08%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Intra-Cellular Therapies Inc

 

Profile

MORE
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of...
Sharon Mates Ph.D.
Chairman of the Board, Chief Executive Officer
Michael Halstead J.D.
President
Lawrence Hineline CPA
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
Suresh Durgam M.D.
Executive Vice President, Chief Medical Officer
Mark Neumann
Executive Vice President, Chief Commercial Officer
Address
430 East 29th Street, Suite 900
New York, NY
10016
United States

Top Peers

SYMBOLLASTCHG%CHG
ASND
Ascendis Pharma A/S
140.15+4.25+3.13%
APLS
Apellis Pharmaceuticals Inc
47.84-2.02-4.05%
CERE
Cerevel Therapeutics Holdings Inc
42.75+0.28+0.66%
VKTX
Viking Therapeutics Inc
75.42+1.11+1.49%
ROIV
Roivant Sciences Ltd
11.13+0.10+0.91%